3rd Quarter - Report

INFUSION PROVIDERS ALLIANCE for INFUSION PROVIDERS ALLIANCE

Firm
Client
Income
—
Expenses
$110,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement for Part B drugs. Issues related to virtual supervision of infusion drugs. Issues related to physician reimbursement to complex drug administration. Issues related to appropriate reimbursement for administration of Part B drugs. H.R. 4299, Protecting Patient Access to Cancer and Complex Therapies Act Issues related to the 2026 Medicare Physician Fee Schedule Proposed Rule (CMS-1832-P).

LobbyistCovered position, as disclosed
ELLIOTT WARREN New —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS)

Bills named: H.R. 4299 (119th)

Health Issues HCR

Advocating for access to and reimbursement for biosimilars.

LobbyistCovered position, as disclosed
ELLIOTT WARREN New —

Contacted: SENATE; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.